Shanghai Hengrun Dasheng Biotech Secures Hundreds of Millions in Series C Funding Led by Yingke Capital

Investment Circle (ID: pedaily2012) reported on April 26 that Shanghai Hengrun Dasheng Biotechnology Co., Ltd. (hereinafter referred to as "Hengrun Dasheng") has finalized its Series C financing, amounting to hundreds of millions of yuan.Yingke CapitalParticipated in this round of financing as the lead investor. Shanghai Hengrun Dasheng Biotechnology Co., Ltd stated that the funds raised will be primarily used for Phase II clinical trials of three non-solid tumor projects and the research and development of next-generation cell immunotherapies, while comprehensively laying out upstream CAR-T cell viral vector production bases and building a CDMO platform serving the entire industry.

Yingke CapitalPartnerProfessor Shi Zhengzheng stated that Shanghai Hengrun Dasheng Biotechnology Co., Ltd. has made the research and application of tumor immunotherapy technologies its breakthrough point, simultaneously translating the latest domestic and international tumor immunotherapy technologies into practice, and actively promoting the development and industrial translation of innovative tumor cell immunotherapy technologies. Fujian Yingke Venture Capital Co., Ltd. is optimistic about Hengrun Dasheng’s R&D advantages and industrial chain layout in the field of cell therapy, represented by CAR-T technology. It believes that this round of financing will further promote the clinical implementation of cell immunotherapy in the cancer field, contributing additional strength to humanity’s efforts to overcome cancer.

Shanghai Hengrun Dasheng Biotechnology Co., Ltd. is an international R&D-focused pharmaceutical company co-founded by renowned experts from the University of Southern California, Duke University, and the University of California, Los Angeles, together with Chinese scientists. Its comprehensive product strength ranks among the leading positions in China and has gained industry recognition. In 2018, the company’s three products for treating leukemia, lymphoma, and multiple myeloma all received acceptance numbers from the Center for Drug Evaluation (CDE) of China, making it the first domestic company to simultaneously initiate three formal CAR-T clinical trials. Furthermore, Hengrun Dasheng pioneered the mastery of mature stable viral vector production processes and established an 11,000-square-meter GMP-compliant CAR-T cell manufacturing base, meeting the industrial-scale production needs for multiple products. This process effectively shortens the production workflow for viruses (a key raw material in CAR-T preparation), significantly reduces production costs, and lays the foundation for large-scale industrialized production of cell therapies.

Cell therapy is considered one of the most promising innovative treatments for conquering cancer. Cancer immunotherapy, represented by CAR-T technology, was ranked as the top global scientific breakthrough of 2013 by Science magazine. The global market size was $734 million in 2019 and is projected to grow to $4.7 billion by 2024, with a compound annual growth rate (CAGR) of approximately 30%, indicating rapid market expansion. CAR-T therapy is currently at a critical stage for broader clinical application and holds broad prospects for the future.

Chairman of Yingke CapitalQian MingfeiMr. [Name] stated that biomedicine is a core investment sector for Fujian Yingke Venture Capital Co., Ltd., and the investment in Shanghai Hengrun Dasheng Biotechnology Co., Ltd. represents another significant strategic decision by the firm in the biomedical field. Going forward, Fujian Yingke Venture Capital will leverage its platform advantages in value investment within the biomedical industry and ecosystem by opening up its existing industrial network resources to Shanghai Hengrun Dasheng Biotechnology and providing comprehensive empowerment support.